RE:May 2022-ESMO - pelareorep "primes" the TME for ICI -AWARE-1November 03, 2023 - Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Further positive translational data from the previously completed AWARE-1 breast cancer window-of-opportunity study, sponsored by SOLTI-Innovative Cancer Research, was presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
"Using the novel IMC technology to conduct further translational data analysis from the AWARE-1 study in early-stage breast cancer patients has confirmed and expanded our understanding of pelareorep's mechanism of action in the tumor microenvironment," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "We look forward to incorporating these important translational learnings into our registrational program for HR+/HER2- metastatic breast cancer. These findings likely also have implications for other indications where we have seen signals of efficacy with atezolizumab/pelareorep combinations, including pancreatic cancer in the GOBLET study focused on gastrointestinal cancers."
Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics, commented, "Previously published analyses from AWARE-1 patient samples showed that in the first three days after dosing, pelareorep upregulated tumor PD-L1 expression in the tumors, induced the generation and expansion of T cell clones, and promoted the tumor infiltration of CD8+ T cells. It also led to an increase in the CelTIL score in most patients, which is a measure of tumor cellularity and immune infiltration that is associated with favorable clinical outcomes. The new IMC data presented today show an increase in cytotoxic T cells and PD-L1 expression in tumors by three days following treatment and demonstrate pela's ability to induce an enhanced immune state within tumors. This supports pelareorep's ability to modify the tumor microenvironment and enhance the responsiveness of cancers to checkpoint inhibitor therapy."
https://www.newswire.ca/news-releases/oncolytics-biotech-r-and-solti-present-further-positive-pelareorep-translational-data-at-sitc-892399838.html